CHMP backs J&J’s myeloma CAR-T therapy Carvykti
pharmaphorum
MARCH 27, 2022
The decision comes less than a month after Carvykti was approved by the FDA as a fifth-line therapy for multiple myeloma, teeing up a tussle in the market with Bristol-Myers Squibb and bluebird bio spinout 2seventy’s Abecma (idecabtagene autoleucel) which was approved for a similar indication last year.
98 
Let's personalize your content